SRR2932824
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.630
- INTERFERON_ALPHA_RESPONSE+0.510
- MYC_TARGETS_V1+0.390
- INTERFERON_GAMMA_RESPONSE+0.340
- HEDGEHOG_SIGNALING+0.310
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
- MTORC1_SIGNALING+0.270
- DNA_REPAIR+0.170
Top 10 suppressed
- APICAL_SURFACE-0.270
- ANGIOGENESIS-0.240
- COAGULATION-0.240
- PROTEIN_SECRETION-0.230
- KRAS_SIGNALING_UP-0.180
- HEME_METABOLISM-0.170
- NOTCH_SIGNALING-0.170
- CHOLESTEROL_HOMEOSTASIS-0.160
- COMPLEMENT-0.160
- ANDROGEN_RESPONSE-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-PQ-A6FI-01A-11R-A31N-07 | — | — | 0.769 |
| 2 | TCGA-T3-A92N-01A-11R-A39I-07 | — | — | 0.752 |
| 3 | TCGA-21-1083-01A-01R-0692-07 | — | cohortMD1 | 0.751 |
| 4 | TCGA-63-A5MJ-01A-11R-A27Q-07 | — | cohortSQ2 | 0.750 |
| 5 | SRR12475159 | — | — | 0.749 |
| 6 | TCGA-CV-5977-01A-11R-1686-07 | — | — | 0.748 |
| 7 | TCGA-OL-A6VO-01A-12R-A33J-07 | — | E | 0.742 |
| 8 | TCGA-HD-7832-01A-11R-2132-07 | — | — | 0.740 |
| 9 | SRR8518219 | — | E | 0.725 |
| 10 | SRR35579801 | — | E | 0.725 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.630 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.170 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.080 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |